GlassScriptPhysician profile
Tanees Iftikhar Edraki
NPI 1881644482
$636.57
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $74.43 · 2021: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $144.43 | 2019-2021 | |
| Amgen INC. | $142.33 | 2019-2021 | |
| Novo Nordisk INC | $97.20 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $67.91 | 2019 | |
| Therapeuticsmd, INC. | $57.05 | 2019-2021 | |
| Allergan, INC. | $27.06 | 2019 | |
| Ascend Therapeutics US, LLC | $24.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.89 | 2021 | |
| Avion Pharmaceuticals | $16.36 | 2019 | |
| Lupin INC. | $16.00 | 2020 | |
| Glaxosmithkline, LLC. | $15.23 | 2021 | |
| Exeltis, USA INC. | $11.61 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanees Edraki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.